Table 3.
Risk factors for in-hospital mortality
| Variables | Survival (N = 426) | In-hospital mortality (N = 63) | Univariate | Multivariate | ||
|---|---|---|---|---|---|---|
| OR (95%CI) | P | aOR (95%CI) | P | |||
| Age, mean (± SD) | 50.9 (± 14.8) | 55.4 (± 14.2) | 1.0 (1.0–1.0) | 0.025 | – | – |
| Male | 250 (58.7) | 33 (52.4) | 0.8 (0.5–1.3) | 0.344 | – | – |
| Chemotherapy | ||||||
| Induction or re-induction | 158 (37.1) | 45 (71.4) | 4.2 (2.4–7.6) | < 0.001 | 3.5 (1.7–7.0) | 0.001 |
| Consolidation | 268 (62.9) | 18 (28.6) | – | – | – | – |
| Diabetes mellitus | 113 (26.5) | 23 (36.5) | 1.6 (0.9–2.8) | 0.099 | – | – |
| Isolation of resistant organism in the prior 1 year | ||||||
| VRE | 27 (6.3) | 17 (27.0) | 5.5 (2.8–10.8) | < 0.001 | 4.3 (1.8–10.2) | 0.001 |
| ESBL | 21 (4.9) | 8 (12.7) | 2.8 (1.2–6.6) | 0.023 | – | – |
| CRPA | 8 (1.9) | 3 (4.8) | 2.6 (0.7–10.1) | 0.158 | – | – |
| CRAB | 4 (0.9) | 5 (7.9) | 9.1 (2.4–34.8) | 0.003 | – | – |
| History of GNB bacteremia in the prior 1 year | 136 (31.9) | 31 (49.2) | 2.1 (1.2–3.5) | 0.007 | – | – |
| Presence of preceding bacteremia during the hospitalization | 42 (9.9) | 19 (30.2) | 3.9 (2.1–7.4) | < 0.001 | – | – |
| Primary foci of infection | ||||||
| Intra-abdominal infection | 66 (15.5) | 6 (9.5) | 0.6 (0.2–1.4) | 0.212 | – | – |
| Central line associated infection | 54 (12.7) | 6 (9.5) | 0.7 (0.3–1.8) | 0.507 | – | – |
| Urinary tract infection | 7 (1.6) | 1 (1.6) | 1.0 (1.1–8.0) | 1.000 | – | – |
| Pneumonia | 2 (0.5) | 4 (6.3) | 14.4 (2.6–80.2) | 0.003 | 32.7 (5.1–208.5) | < 0.001 |
| Others | 9 (2.1) | 0 (0.0) | 0.9 (0.8–0.9) | 0.374 | – | – |
| Unknown | 288 (67.6) | 46 (73.0) | 1.3 (0.7–2.3) | 0.389 | – | – |
| Pitt score, median (IQR) | 1.3 (0.0–2.0) | 4.1 (1.0–5.0) | 1.5 (1.3–1.7) | < 0.001 | 1.5 (1.3–1.7) | < 0.001 |
| Septic shock | 73 (17.1) | 29 (46.0) | 4.1 (2.4–7.2) | < 0.001 | – | – |
| Carba-NS | 24 (5.6) | 21 (33.3) | 8.4 (4.3–16.3) | < 0.001 | 6.6 (3.0–14.8) | < 0.001 |
| Inappropriate empiric antibiotics | 27 (6.3) | 13 (20.6) | 3.8 (1.9–7.9) | < 0.001 | – | – |
| Hospital stay, median | ||||||
| Days from chemotherapy to GNB bacteremia, median (IQR) | 14.2 (11.0–16.0) | 18.0 (11.0–21.0) | 1.1 (1.0–1.1) | < 0.001 | – | – |
| Hospital days to GNB bacteremia, median (IQR) | 21.2 (14.0–20.0) | 40.3 (18.0–61.0) | 1.0 (1.0–1.1) | < 0.001 | – | – |
OR odds ratio, aOR adjusted odds ratio, CI confidence interval, SD standard deviation, VRE vancomycin resistant enterococci, ESBL extended-spectrum β-lactamase-producing enterobacteriaceae, CRPA carbapenem resistant Pseudomonas aeruginosa, CRAB carbapenem resistant Acinetobacter baumannii, GNB gram negative bacilli, IQR interquartile range, Carba-NS carbapenem non-susceptible